Unlabelled: PET/CT with (18)F-FDG is an important noninvasive diagnostic tool for management of patients with lymphoma, and its use may surpass current guideline recommendations. The aim of the present study is to enlarge the growing body of evidence concerning (18)F-FDG avidity of lymphoma to provide a basis for future guidelines.
Methods: The reports from (18)F-FDG PET/CT studies performed in a single center for staging of 1,093 patients with newly diagnosed Hodgkin disease and non-Hodgkin lymphoma between 2001 and 2008 were reviewed for the presence of (18)F-FDG avidity. Of these patients, 766 patients with a histopathologic diagnosis verified according to the World Health Organization classification were included in the final analysis. (18)F-FDG avidity was defined as the presence of at least 1 focus of (18)F-FDG uptake reported as a disease site. Nonavidity was defined as disease proven by clinical examination, conventional imaging modalities, and histopathology with no (18)F-FDG uptake in any of the involved sites.
Results: At least one (18)F-FDG-avid lymphoma site was reported for 718 patient studies (94%). Forty-eight patients (6%) had lymphoma not avid for (18)F-FDG. (18)F-FDG avidity was found in all patients (100%) with Hodgkin disease (n = 233), Burkitt lymphoma (n = 18), mantle cell lymphoma (n = 14), nodal marginal zone lymphoma (n = 8), and lymphoblastic lymphoma (n = 6). An (18)F-FDG avidity of 97% was found in patients with diffuse large B-cell lymphoma (216/222), 95% for follicular lymphoma (133/140), 85% for T-cell lymphoma (34/40), 83% for small lymphocytic lymphoma (24/29), and 55% for extranodal marginal zone lymphoma (29/53).
Conclusion: The present study indicated that with the exception of extranodal marginal zone lymphoma and small lymphocytic lymphoma, most lymphoma subtypes have high (18)F-FDG avidity. The cumulating evidence consistently showing high (18)F-FDG avidity in the potentially curable Burkitt, natural killer/T-cell, and anaplastic large T-cell lymphoma subtypes justifies further investigations of the utility of (18)F-FDG PET in these diseases at presentation.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2967/jnumed.109.067892 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
18F-FDG PET/CT Revealed Bone Infarction as the Cause of Unexplained Fever.
Clin Nucl Med
December 2024
From the Department of Nuclear Medicine, Peking University First Hospital, Beijing.
An 18F-FDG PET/CT was conducted on a 44-year-old man with a history of dermatomyositis and avascular necrosis of left femoral head, due to a fever of unknown origin. The scan revealed patchy and cloudy high densities within the medullary cavities of bilateral distal femur and proximal tibia, exhibiting peripheral high 18F-FDG avidity. Subsequent MRI confirmed bone infarction.
View Article and Find Full Text PDFA Rare Case of High-Grade Fetal Adenocarcinoma of the Lung Demonstrated by 18F-FDG PET/CT.
Clin Nucl Med
December 2024
Department of Nuclear Medicine, The First Affiliated Hospital of Naval Medical University, Shanghai, China.
An 85-year-old non-smoking woman with right back pain for 1 month underwent a chest CT, which showed a mass with a maximum diameter of 12.2 cm in the upper lobe of right lung. The lesion demonstrated heterogeneous uptake on FDG PET scanning.
View Article and Find Full Text PDF[18F]-Fluorodeoxyglucose Uptake as a Marker of Residual Anaplastic and Poorly Differentiated Thyroid Carcinoma Following BRAF-Targeted Therapy.
AJNR Am J Neuroradiol
November 2024
From the Department of Neuroradiology / Head and Neck Imaging (S.A.D., K.O.L., R.D., A.M.K.), Department of Head and Neck Surgery (J.R.W., X.Z., A.M., M.E.Z.), Department of Pathology (S.M.H.), and Department of Endocrine Neoplasia and Hormonal Disorders (M.E.C., N.L.B., R.D., P.I.), The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Background And Purpose: Neoadjuvant BRAF-directed therapy and immunotherapy followed by surgery improves survival in patients with BRAF-mutant anaplastic thyroid carcinoma (ATC), more so in those who have complete ATC pathologic response. This study assesses the ability of FDG-PET to non-invasively detect residual high-risk pathologies including ATC and poorly differentiated thyroid carcinoma (PDTC) in the preoperative setting.
Materials And Methods: This retrospective, single-center study included consecutive BRAF-mutant ATC patients treated with at least 30 days of neoadjuvant BRAF-directed therapy and who underwent FDG-PET/CT within 30 days prior to surgery.
[Clinical Value of Dual Tracer PET Imaging With Ga-PSMA and F-FDG in Patients With Metastatic Prostate Cancer].
Sichuan Da Xue Xue Bao Yi Xue Ban
September 2024
（ 610041） Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu 610041, China.
Objective: In this study, we retrospectively analyzed the imaging characteristics of dual-tracer Ga-prostate specific membrane antigen (PSMA) and F-flurodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) in metastatic prostate cancer (mPCa) patients. We analyzed the uptake modes of the dual tracers, explored clinical pathological parameters affecting the F-FDG uptake in the lesions, and evaluated their prognostic implications for prostate specific antigen progression-free survival (PSA-PFS).
Methods: A total of 41 mPCa patients who underwent dual-tracer PET/CT (Ga-PSMA and F-FDG) scans between September 2021 and January 2024 were retrospectively enrolled.
[18F]-Fluoroestradiol (FES) brain PET in the evaluation of patients with estrogen receptor positive breast cancer and known or suspected brain metastases.
Eur J Radiol
December 2024
Weill Cornell Medicine, Department of Neurological Surgery, New York, NY, USA.
Objective: Our purpose was to describe our initial institutional experience using dedicated brain [18F]-Fluoroestradiol (FES) PET/CT or PET/MRI in the management of patients with estrogen-receptor-positive (ER+) breast cancer brain metastases (BCBM), and compare to [18F]-Fluorodeoxyglucose (FDG) PET and MRI.
Materials & Methods: Patients with biopsy-proven ER+ disease and MRI findings of suspected new, progressive, or recurrent BCBM were included in this retrospective study. Clinical and demographic data were collected.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!